About Jonathan Fleming
Jonathan Fleming is a director of Quiver Bioscience, a drug discovery company. He is chairman of the board at AutonomoUS, Diceros Therapeutics, Onc.AI, Aquaculture Research Corporation and EnClear Therapies. He is also a board member at CONTINUUS Pharmaceuticals. He has been a senior lecturer at the MIT Sloan School of Management since 2002. He co-teaches a business strategy class for life science managers.
Fleming was managing partner of Oxford Bioscience Partners for 19 years and joined the firm in 1996. From 1988 to 1996 he was a founding general partner of MVP Ventures in Boston. He co-founded several neuroscience companies, including Synaptic Pharmaceuticals, Memory Pharmaceuticals and Hypnion Pharmaceuticals. Lundbeck acquired Synaptic, Roche acquired Memory, and Lilly acquired Hypnion. He is a former president and chief executive officer of Q-State Biosciences and executive chairman of QurAlis. He has a master's degree in public administration from Princeton University and a bachelor's degree in political science from the University of California, Berkeley.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Jonathan Fleming in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jonathan Fleming works with at each company, as listed on that company's latest Form D.
Jonathan Fleming in the News
Sources
- SECQuiver Holdings Inc. Form D, filed Oct 21, 2026
- SECDiceros Therapeutics, Inc. Form D/A, filed Aug 5, 2024
- SECEnClear Therapies, Inc. Form D, filed Mar 1, 2024
- SECAquacultural Research Corp Form D, filed Jan 12, 2024
- SECQurAlis Corp Form D, filed May 18, 2020
- SECForms 3, 4 and 5 filed by Jonathan Fleming (SEC filer 1262294)
- companyQuiver Bioscience people page
- secRadius Health S-1/A, November 7, 2011 (director biography)